KRW 19460.0
(-4.61%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 9.16 Billion KRW | -33.55% |
2022 | 13.79 Billion KRW | 43.78% |
2021 | 9.59 Billion KRW | 38.05% |
2020 | 6.94 Billion KRW | 29.56% |
2019 | 5.36 Billion KRW | -6.61% |
2018 | 5.74 Billion KRW | 50.21% |
2017 | 3.82 Billion KRW | 59.47% |
2016 | 2.39 Billion KRW | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 2.47 Billion KRW | -1.92% |
2024 Q2 | 2.95 Billion KRW | 19.72% |
2023 FY | 9.16 Billion KRW | -33.55% |
2023 Q2 | 2.47 Billion KRW | 15.26% |
2023 Q3 | 2.03 Billion KRW | -17.79% |
2023 Q4 | 2.51 Billion KRW | 24.03% |
2023 Q1 | 2.14 Billion KRW | -61.48% |
2022 Q2 | 2.02 Billion KRW | -21.09% |
2022 FY | 13.79 Billion KRW | 43.78% |
2022 Q4 | 5.56 Billion KRW | 52.92% |
2022 Q3 | 3.63 Billion KRW | 79.91% |
2022 Q1 | 2.56 Billion KRW | 5.93% |
2021 Q3 | 2.2 Billion KRW | 0.0% |
2021 Q4 | 2.42 Billion KRW | 9.78% |
2021 FY | 9.59 Billion KRW | 38.05% |
2020 FY | 6.94 Billion KRW | 29.56% |
2019 FY | 5.36 Billion KRW | -6.61% |
2018 FY | 5.74 Billion KRW | 50.21% |
2017 FY | 3.82 Billion KRW | 59.47% |
2016 FY | 2.39 Billion KRW | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
HLB Pharmaceutical Co., Ltd | 102.52 Billion KRW | 91.06% |
CMG Pharmaceutical Co., Ltd. | 37.86 Billion KRW | 75.793% |
Celltrion Pharm, Inc. | 80.93 Billion KRW | 88.675% |
Huons Global Co., Ltd. | 294.87 Billion KRW | 96.892% |
DongKook Pharmaceutical Co., Ltd. | 338.16 Billion KRW | 97.289% |
Enzychem Lifesciences Corporation | 18.7 Billion KRW | 50.994% |
Humedix Co., Ltd. | 33.04 Billion KRW | 72.26% |
Boditech Med Inc. | 47.05 Billion KRW | 80.519% |
EuBiologics Co., Ltd. | 24.95 Billion KRW | 63.277% |
Huons Co., Ltd. | 226.14 Billion KRW | 95.947% |
BNC Korea Co., Ltd. | 25.19 Billion KRW | 63.625% |
AptaBio Therapeutics Inc. | 16.45 Billion KRW | 44.285% |